Institutional Repository in Medical Sciences
(IRMS – Nicolae Testemițanu SUMPh)

Vaginal progesterone decreases preterm birth < 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the opptimum study

Show simple item record

dc.contributor.author Romero, R.
dc.contributor.author Nicolaides, K. H.
dc.contributor.author Conde-Agudelo, A.
dc.contributor.author O’Brien, J. M.
dc.contributor.author Cetingoz, E.
dc.contributor.author Fonseca, E. DA
dc.contributor.author Creasy, G. W.
dc.contributor.author Hassan, S. S.
dc.date.accessioned 2021-06-10T19:39:54Z
dc.date.available 2021-06-10T19:39:54Z
dc.date.issued 2017
dc.identifier.citation ROMERO, R., NICOLAIDES, K. H., CONDE-AGUDELO, A., et al. Vaginal progesterone decreases preterm birth < 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the opptimum study. In: Buletin de perinatologie. 2017, nr. 4(76), pp. 27-38. ISSN 1810-5289. en_US
dc.identifier.issn 1810-5289
dc.identifier.uri https://ibn.idsi.md/sites/default/files/j_nr_file/Buletin%20de%20Perinatologie_4_2017.pdf
dc.identifier.uri http://repository.usmf.md/handle/20.500.12710/17670
dc.description Perinatology Research Branch, Program for Perinatal Research and Obstetrics, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Department of Health and Human Services, Bethesda, MD and Detroit, MI, USA, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, MI, USA, Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, MI, USA, Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI, USA, Harris Birthright Research Centre for Fetal Medicine, King’s College Hospital, London, UK, Department of Obstetrics and Gynecology, University of Kentucky, Lexington, KY, USA, Department of Obstetrics and Gynecology, Zeynep Kamil Women and Children Diseases Education and Research Hospital, Uskudar, Istanbul, Turkey, Departamento de Obstetricia e Ginecologia, Hospital do Servidor Publico Estadual ‘Francisco Morato de Oliveira’ and School of Medicine, University of Sao Paulo, Sao Paulo, Brazil, Center for Biomedical Research, Population Council, New York, NY, USA, Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, MI, USA en_US
dc.description.abstract Objective. To evaluate the efficacy of vaginal progesterone administration for preventing preterm birth and perinatal morbidity and mortality in asymptomatic women with a singleton gestation and a mid-trimester sonographic cervical length (CL) < 25 mm. Methods. This was an updated systematic review and meta-analysis of randomized controlled trials comparing the use of vaginal progesterone to placebo/no treatment in women with a singleton gestation and a mid-trimester sonographic CL < 25 mm. Electronic databases, from their inception to May 2016, bibliographies and conference proceedings were searched. The primary outcome measure was preterm birth < 34 weeks of gestation or fetal death. Two reviewers independently selected studies, assessed the risk of bias and extracted the data. Pooled relative risks (RRs) with 95% confidence intervals (CI) were calculated. Results. Five trials involving 974 women were included. A meta-analysis, including data from the OPPTIMUM study, showed that vaginal progesterone significantly decreased the risk of preterm birth < 34 weeks of gestation or fetal death compared to placebo (18.1% vs 27.5%; RR, 0.66 (95% CI, 0.52-0.83); P = 0.0005; five studies; 974 women). Meta-analyses of data from four trials (723 women) showed that vaginal progesterone administration was associated with a statistically significant reduction in the risk of preterm birth occurring at < 28 to < 36 gestational weeks (RRs from 0.51 to 0.79), respiratory distress syndrome (RR, 0.47 (95% CI, 0.27-0.81)), composite neonatal morbidity and mortality (RR, 0.59 (95% CI, 0.38-0.91)), birth weight < 1500g (RR, 0.52 (95% CI, 0.34-0.81)) and admission to the neonatal intensive care unit (RR, 0.67 (95% CI, 0.50-0.91)). There were no significant differences in neurodevelopmental outcomes at 2 years of age between the vaginal progesterone and placebo groups. Conclusion. This updated systematic review and meta-analysis reaffirms that vaginal progesterone reduces the risk of preterm birth and neonatal morbidity and mortality in women with a singleton gestation and a mid-trimester CL < 25 mm, without any deleterious effects on neurodevelopmental outcome. Clinicians should continue to perform universal transvaginal CL screening at 18-24 weeks of gestation in women with a singleton gestation and to offer vaginal progesterone to those with a CL < 25 mm. Published 2016. This article is a U.S. Government work and is in the public domain in the USA. en_US
dc.language.iso en en_US
dc.publisher Instituţia Medico-Sanitară Publică Institutul Mamei și Copilului en_US
dc.relation.ispartof Buletin de perinatologie en_US
dc.subject cervical length en_US
dc.subject neonatal morbidity en_US
dc.subject neonatal mortality en_US
dc.subject prematurity en_US
dc.subject preterm delivery en_US
dc.subject progestins en_US
dc.subject progestogens en_US
dc.subject transvaginal ultrasound en_US
dc.title Vaginal progesterone decreases preterm birth < 34 weeks of gestation in women with a singleton pregnancy and a short cervix: an updated meta-analysis including data from the opptimum study en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record

Search DSpace


Advanced Search

Browse

My Account

Statistics